Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1996 Jul 6;313(7048):33–35. doi: 10.1136/bmj.313.7048.33

Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.

K Bloor 1, A Maynard 1, N Freemantle 1
PMCID: PMC2351415  PMID: 8664771

Abstract

This is the third of three papers that review international policies to control spending on drugs and to improve the efficiency of drug use. This paper reviews policies regulating the supply of drugs, particularly licensing and reimbursement controls, price and profit regulation. Price and profit controls contain few incentives for improving cost effective use of drugs, and focus on cost containment and profitability of domestic industry. Carefully monitored economic evaluation could lead to improvements in efficiency and benefits to patients and the health care system.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Detsky A. S. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics. 1993 May;3(5):354–361. doi: 10.2165/00019053-199303050-00003. [DOI] [PubMed] [Google Scholar]
  2. Freemantle N., Henry D., Maynard A., Torrance G. Promoting cost effective prescribing. BMJ. 1995 Apr 15;310(6985):955–956. doi: 10.1136/bmj.310.6985.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Garattini L., Salvioni F., Scopelliti D., Garattini S. A comparative analysis of the pharmaceutical market in four European countries. Pharmacoeconomics. 1994 Nov;6(5):417–423. doi: 10.2165/00019053-199406050-00003. [DOI] [PubMed] [Google Scholar]
  4. Gross D. J., Ratner J., Perez J., Glavin S. L. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom. Health Care Financ Rev. 1994 Spring;15(3):127–140. [PMC free article] [PubMed] [Google Scholar]
  5. Hutton J., Borowitz M., Oleksy I., Luce B. R. The pharmaceutical industry and health reform: lessons from Europe. Health Aff (Millwood) 1994 Summer;13(3):98–111. doi: 10.1377/hlthaff.13.3.98. [DOI] [PubMed] [Google Scholar]
  6. Jönsson B. Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics. 1994;6 (Suppl 1):51–60. doi: 10.2165/00019053-199400061-00013. [DOI] [PubMed] [Google Scholar]
  7. Lyons J. S., Larson D. B. Regulations controlling costs of drugs: a perspective from the US. Pharmacoeconomics. 1992 Aug;2(2):91–94. doi: 10.2165/00019053-199202020-00001. [DOI] [PubMed] [Google Scholar]
  8. Pelc A., Castan J. P. New developments in pricing and drug reimbursement in France. Pharmacoeconomics. 1994;6 (Suppl 1):28–35. doi: 10.2165/00019053-199400061-00009. [DOI] [PubMed] [Google Scholar]
  9. Reeder C. E., Lingle E. W., Schulz R. M., Mauch R. P., Jr, Nightengale B. S., Pedersen C. A., Watrous M. L., Zetzl S. E. Economic impact of cost-containment strategies in third party programmes in the US (part I). Pharmacoeconomics. 1993 Aug;4(2):92–103. doi: 10.2165/00019053-199304020-00004. [DOI] [PubMed] [Google Scholar]
  10. Rigter H. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics. 1994;6 (Suppl 1):15–21. doi: 10.2165/00019053-199400061-00007. [DOI] [PubMed] [Google Scholar]
  11. vd Schulenburg J. M. The German health care system at the crossroads. Health Econ. 1994 Sep-Oct;3(5):301–303. doi: 10.1002/hec.4730030503. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES